Celyad Oncology S.A.
CLYYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.06 | 0.02 | 0.10 |
| FCF Yield | 0.00% | -9.66% | -40.76% | -66.25% |
| EV / EBITDA | -4.33 | -16.46 | -0.61 | -1.15 |
| Quality | ||||
| ROIC | -179.96% | -39.15% | -28.71% | -33.88% |
| Gross Margin | -1,414.29% | -30.23% | 35.71% | 56.90% |
| Cash Conversion Ratio | – | 1.02 | 0.93 | 1.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 186.25% | 196.94% | -42.43% | -68.03% |
| Free Cash Flow Growth | 100.00% | -0.64% | 62.02% | 14.13% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -5.13 | 1.88 | 1.37 |
| Interest Coverage | -88.10 | -51.55 | -50.54 | -74.79 |
| Efficiency | ||||
| Inventory Turnover | 0.83 | 0.54 | 0.00 | 0.00 |
| Cash Conversion Cycle | 4,602.98 | 147.26 | -10,124.29 | -3,885.14 |